Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.

Current cancer drug targets - 1 Feb 2012

Cejas P, López-Gómez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Díaz E, Burgos E, Gonzalez-Barón M, Feliu J

Abstract excerpt

Patients with metastatic Colorectal Cancer (mCRC), in which primary tumors are KRAS mutated, have no response to anti-EGFR therapy. However, less than half of mCRC patients with KRAS wild-type primary tumors respond to anti-EGFR therapy. Other downstream effectors of the EGFR pathway are being analyzed to fine-tune KRAS predictive value. However, as the primary tumor is the tissue of analysis that determines the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genes, ras

Share to Immunohistochemistry

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Source

Identifiers

PMID: 22229245
DOI: 10.2174/156800912799095162

Genes

EGFR
KRAS
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.PMID 22229245Read ↗

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.Semantic proximity Read ↗

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.Semantic proximity Read ↗

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.Semantic proximity Read ↗

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.Semantic proximity Read ↗

Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.Semantic proximity Read ↗

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.Semantic proximity Read ↗

KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.Semantic proximity Read ↗

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.Semantic proximity Read ↗

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer.Semantic proximity Read ↗

High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.